Evidence map›Paper›PMID 41624793›Full record

ArticleFrontiers in cell and developmental biology2025

PTEN enhances the radiosensitivity of melanoma by inhibiting DNA-PKcs.

Shengqian Zhu, Haitao Xu, Fu Shen, Fangying Chen, Yangjian Wang

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shengqian ZhuDepartment of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Haitao XuDepartment of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Fu ShenDepartment of Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Fangying ChenDepartment of Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Yangjian WangDepartment of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The phosphatase and tensin homolog ( Methods: The expression of PTEN was validated using TCGA database, clinical tissue microarrays, and multiple melanoma cell lines. PTEN knockdown (PTEN-KD) and PTEN overexpression (PTEN-OE) stable cell lines were constructed using lentiviral vectors. CCK-8, colony formation assay, annexin V/PI flow cytometry, neutral comet assay, cell-cycle analysis, and Western blotting were used to assess the biological changes in cells after 0 Gy-8 Gy γ-ray irradiation (IR). A cell-derived xenograft model was established, and the tumor volume was observed after local 10 Gy IR for 28 days; in addition, H&E, Ki67, and TUNEL evaluations were performed. Results: The expression of PTEN in melanoma tissues and cell lines was significantly lower than that in normal controls. IR could induce a transient upregulation of PTEN followed by rapid downregulation. PTEN-OE significantly inhibited proliferation, reduced the clone survival rate, increased apoptosis, and weakened radiation-induced G Conclusion: PTEN enhances the radiosensitivity of melanoma by inhibiting the DNA-PKcs signal, weakening NHEJ repair, and delaying cell-cycle recovery. PTEN can serve as a biomarker for radiotherapy response prediction and a target for sensitization intervention, providing an experimental basis for precise radiotherapy strategies for melanoma.

Indexed as

DNA damage repairimmunotherapyirradiationmelanomaPTEN

Identifiers

PMID41624793
PMCPMC12851971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.